Rosell, R., & Thomas, M. (2017). Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): An international, multicentre, single-arm, phase 2 trial. The lancet. Respiratory medicine, 5(5), . https://doi.org/10.1016/S2213-2600(17)30129-7
Chicago-Zitierstil (17. Ausg.)Rosell, Rafael, und Michael Thomas. "Erlotinib and Bevacizumab in Patients with Advanced Non-small-cell Lung Cancer and Activating EGFR Mutations (BELIEF): An International, Multicentre, Single-arm, Phase 2 Trial." The Lancet. Respiratory Medicine 5, no. 5 (2017). https://doi.org/10.1016/S2213-2600(17)30129-7.
MLA-Zitierstil (9. Ausg.)Rosell, Rafael, und Michael Thomas. "Erlotinib and Bevacizumab in Patients with Advanced Non-small-cell Lung Cancer and Activating EGFR Mutations (BELIEF): An International, Multicentre, Single-arm, Phase 2 Trial." The Lancet. Respiratory Medicine, vol. 5, no. 5, 2017, https://doi.org/10.1016/S2213-2600(17)30129-7.